125 related articles for article (PubMed ID: 25931139)
1. Small-molecule compounds exhibiting target-mediated drug disposition - A case example of ABT-384.
An G; Liu W; Dutta S
J Clin Pharmacol; 2015 Oct; 55(10):1079-85. PubMed ID: 25931139
[TBL] [Abstract][Full Text] [Related]
2. Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Minireview.
An G
J Clin Pharmacol; 2017 Feb; 57(2):137-150. PubMed ID: 27489162
[TBL] [Abstract][Full Text] [Related]
3. General Pharmacokinetic Features of Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Simulation-Based Study.
Bach T; Jiang Y; Zhang X; An G
J Clin Pharmacol; 2019 Mar; 59(3):394-405. PubMed ID: 30387863
[TBL] [Abstract][Full Text] [Related]
4. Importance of Target-Mediated Drug Disposition (TMDD) of Small-Molecule Compounds and Its Impact on Drug Development-Example of the Class Effect of HSD-1 Inhibitors.
An G; Katz DA
J Clin Pharmacol; 2023 May; 63(5):526-538. PubMed ID: 36479709
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers following single and multiple dose regimens.
An G; Liu W; Katz DA; Marek GJ; Awni W; Dutta S
Biopharm Drug Dispos; 2014 Oct; 35(7):417-29. PubMed ID: 25041811
[TBL] [Abstract][Full Text] [Related]
6. Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds.
An G
J Clin Pharmacol; 2020 Feb; 60(2):149-163. PubMed ID: 31793004
[TBL] [Abstract][Full Text] [Related]
7. Effect of ketoconazole on the pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 and its two active metabolites in healthy volunteers: population analysis of data from a drug-drug interaction study.
An G; Liu W; Katz DA; Marek G; Awni W; Dutta S
Drug Metab Dispos; 2013 May; 41(5):1035-45. PubMed ID: 23431112
[TBL] [Abstract][Full Text] [Related]
8. Target-Mediated Drug Disposition-A Class Effect of Soluble Epoxide Hydrolase Inhibitors.
An G; Lee KSS; Yang J; Hammock BD
J Clin Pharmacol; 2021 Apr; 61(4):531-537. PubMed ID: 33078430
[TBL] [Abstract][Full Text] [Related]
9. A Target-Mediated Drug Disposition Model to Explain Nonlinear Pharmacokinetics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor SPI-62 in Healthy Adults.
Wu N; Katz DA; An G
J Clin Pharmacol; 2021 Nov; 61(11):1442-1453. PubMed ID: 34110620
[TBL] [Abstract][Full Text] [Related]
10. Target-mediated drug disposition and dynamics.
Mager DE
Biochem Pharmacol; 2006 Jun; 72(1):1-10. PubMed ID: 16469301
[TBL] [Abstract][Full Text] [Related]
11. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.
Gibiansky L; Gibiansky E
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):803-12. PubMed ID: 19505189
[TBL] [Abstract][Full Text] [Related]
12. Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Rohde JJ; Pliushchev MA; Sorensen BK; Wodka D; Shuai Q; Wang J; Fung S; Monzon KM; Chiou WJ; Pan L; Deng X; Chovan LE; Ramaiya A; Mullally M; Henry RF; Stolarik DF; Imade HM; Marsh KC; Beno DW; Fey TA; Droz BA; Brune ME; Camp HS; Sham HL; Frevert EU; Jacobson PB; Link JT
J Med Chem; 2007 Jan; 50(1):149-64. PubMed ID: 17201418
[TBL] [Abstract][Full Text] [Related]
13. Target-mediated exposure enhancement: a previously unexplored limit of TMDD.
Glassman PM; Muzykantov VR
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):411-420. PubMed ID: 32488574
[TBL] [Abstract][Full Text] [Related]
14. Characterizing the Nonlinear Pharmacokinetics and Pharmacodynamics of BI 187004, an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, in Humans by a Target-Mediated Drug Disposition Model.
Yuan X; An G
J Clin Pharmacol; 2024 Apr; ():. PubMed ID: 38652112
[TBL] [Abstract][Full Text] [Related]
15. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
Cao Y; Jusko WJ
J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917
[TBL] [Abstract][Full Text] [Related]
16. Population Target-Mediated Pharmacokinetic/Pharmacodynamic Modeling to Evaluate SPI-62 Exposure and Hepatic 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition in Healthy Adults.
Wu N; Katz DA; An G
Clin Pharmacokinet; 2023 Sep; 62(9):1275-1288. PubMed ID: 37452998
[TBL] [Abstract][Full Text] [Related]
17. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
18. A Pharmacometrics Model to Characterize a New Type of Target-Mediated Drug Disposition (TMDD) - Nonlinear Pharmacokinetics of Small-Molecule PF-07059013 Mediated By Its High-capacity Pharmacological Target Hemoglobin With Positive Cooperative Binding.
Xu M; An G
AAPS J; 2023 Apr; 25(3):41. PubMed ID: 37055588
[TBL] [Abstract][Full Text] [Related]
19. Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):463-475. PubMed ID: 28725976
[TBL] [Abstract][Full Text] [Related]
20. Target-mediated drug disposition model for drugs that bind to more than one target.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
